News

Genialis announced a collaborative partnership with Oncologie, an international, clinical-stage biopharma developing next-generation immunotherapies for cancer. Initial activities will…
Read More...

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. for $68 per share in cash. “The acquisition of Synthorx perfectly aligns with our R&D strategy,…
Read More...

Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of…
Read More...

Moderna, Inc. a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and…
Read More...

Catalent welcomed the news that DiaMedica Therapeutics has received U.S. Food and Drug Administration (FDA) approval to commence Phase 2 clinical trials of its lead candidate, DM199,…
Read More...

Roche announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA). The…
Read More...

Epizyme, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TAZVERIK (tazemetostat) for the treatment of adults and pediatric patients…
Read More...

INHIBITOR Therapeutics, Inc. a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous and…
Read More...

Roche announced that the European Commission has granted conditional marketing authorisation for Polivy (polatuzumab vedotin), in combination with bendamustine plus MabThera (rituximab)…
Read More...

Bellicum Pharmaceuticals announced it has entered into an asset purchase agreement under which The University of Texas MD Anderson Cancer Center will acquire Bellicum’s approximately…
Read More...

Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two…
Read More...

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co., Ltd. that engages in contract manufacturing and manufacturing development of cell…
Read More...

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved TEPEZZATM (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is…
Read More...

GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) granted a priority review for the company’s Biologics License Application (BLA) seeking approval of belantamab…
Read More...

Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and…
Read More...

Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now…
Read More...

AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment…
Read More...

Novartis announced the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active…
Read More...

Mundipharma announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong. The partnership covers Samsung…
Read More...

Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced that the Investigational New Drug (IND) application submitted to…
Read More...